J Korean Med Assoc.  2015 Oct;58(10):878-885. 10.5124/jkma.2015.58.10.878.

Benign prostate hyperplasia

• Kim HJ

• KMID: 2195102
• DOI: http://doi.org/10.5124/jkma.2015.58.10.878

Abstract

The rapid aging of the world population is major global demographic trend. The number of people with age-related disease has increased substantially due to increased life expectancy in the general population. Major geriatric urological diseases include urinary incontinence, urological cancer, bladder outlet obstruction disorders such as benign prostatic hyperplasia (BPH), sexual dysfunction, and urinary tract infection. BPH is the most common benign tumor in urology. Testosterone is considered to play a major role in the development of BPH. Lower urinary tract symptoms due to BPH are classified as related to either storage or voiding. Evaluation of symptom scores, digital rectal examination, urine analysis, serum prostate specific antigen measurement, uroflowmetry, and post-void residual urine testing are mandatory. In addition, in order to rule out prostatic cancer, other screening and diagnostic procedures are often required. Depending on the condition of the patients, approaches such as watchful waiting, pharmacotherapy with an alpha blocker or 5-alpha reductase inhibitor, or surgery such as transurethral resection of prostate are appropriate.

Keyword

Prostate; Aging; Geriatrics

MeSH Terms

Aging
Digital Rectal Examination
Drug Therapy
Geriatrics
Humans
Hyperplasia*
Life Expectancy
Lower Urinary Tract Symptoms
Mass Screening
Oxidoreductases
Prostate*
Prostate-Specific Antigen
Prostatic Hyperplasia
Prostatic Neoplasms
Testosterone
Transurethral Resection of Prostate
Urinary Bladder Neck Obstruction
Urinary Incontinence
Urinary Tract Infections
Urologic Diseases
Urologic Neoplasms
Urology
Watchful Waiting
Oxidoreductases
Prostate-Specific Antigen
Testosterone

Reference

1. Haidinger G, Temml C, Schatzl G, Brossner C, Roehlich M, Schmidbauer CP, Madersbacher S. Risk factors for lower urinary tract symptoms in elderly men: for the Prostate Study Group of the Austrian Society of Urology. Eur Urol. 2000; 37:413–420.

2. Krogh J, Jensen JS, Iversen HG, Andersen JT. Age as a prognostic variable in patients undergoing transurethral prostatectomy. Scand J Urol Nephrol. 1993; 27:225–229.

3. Statistics Korea. Statistics of elderly person. [Internet]. Daejeon: Statistics Korea;cited 2015 Sep 27. Available from: http://kostat.go.kr/portal/korea/kor_nw/3/index.board?bmode=read&aSeq=330353.

4. Health Insurance Review and Assessment Service. Stastistics of disease/frequent disease [Internet]. Seoul: Health Insurance Review and Assessment Service;2014. cited 2015 Sep 27. Available from: http://www.hira.or.kr/rd/dissdic/hifreqdiseInfo.do?pgmid=HIRAA020044020400.

5. Sohn HC. Diagnosis of benign prostate hyperplasia. Korean Continence Society. Textbook of voiding difficulty and female urology. 3rd ed. Seoul: Korean Continence Society;2015. p. 413–422.

6. Abrams PH, Farrar DJ, Turner-Warwick RT, Whiteside CG, Feneley RC. The results of prostatectomy: a symptomatic and urodynamic analysis of 152 patients. J Urol. 1979; 121:640–642.

7. Nielsen KK. Changes in morphology, function and blood flow in mini-pig urinary bladder after chronic outflow obstruction and recovery from obstruction. Scand J Urol Nephrol Suppl. 1997; 195:1–39.

8. Roehrborn CG. Pathology of benign prostatic hyperplasia. Int J Impot Res. 2008; 20:Suppl 3. S11–S18.

9. Hong SJ. Benign prostatic hyperplasia: multiple factors for prostate tissue change with aging. Korean J Urol. 2005; 46:547–554.

10. O'Leary MP. Tamsulosin: current clinical experience. Urology. 2001; 58:6 Suppl 1. 42–48.

11. Emberton M, Andriole GL, de la Rosette J, Djavan B, Hoefner K, Vela Navarrete R, Nordling J, Roehrborn C, Schulman C, Teillac P, Tubaro A, Nickel JC. Benign prostatic hyperplasia: a progressive disease of aging men. Urology. 2003; 61:267–273.

12. Sanda MG, Doehring CB, Binkowitz B, Beaty TH, Partin AW, Hale E, Stoner E, Walsh PC. Clinical and biological characteristics of familial benign prostatic hyperplasia. J Urol. 1997; 157:876–879.

13. Park CH. General management, watchful waiting and medica-tion of benign prostate hyperplasia. Korean Continence Society. Textbook of voiding difficulty and female urology. 3rd ed. Korean Continence Society;2015. p. 423–433.

14. Lee SH. Surgical treatment of benign prostate hyperplasia.Korean Continence Society. Textbook of voiding difficulty and female urology. 3rd ed. Seoul: Korean Continence Society;2015. p. 434–447.

15. McConell JD, Barry MD, Bruskewitz RC. Benign prostattic hyperplasia: diagnosis and treatment. Clinical practice guide-line. Rockville: Agency for Health Care Policy and Research;1994.

16. Nudell DM, Cattolica EV. Transurethral prostatectomy: an update. AUA Update Ser. 2000; 19:34–40.

17. Shingleton WB, Farabaugh P, May W. Three-year follow-up of laser prostatectomy versus transurethral resection of the prostate in men with benign prostatic hyperplasia. Urology. 2002; 60:305–308.

18. Montorsi F, Naspro R, Suardi N, Colombo R, Salonia A, Cestari A, Guazzoni G, Digirolamo V, Rigatti P. Holmium laser enucleation of the prostate (HoLEP) versus open prostatectomy for prostates >70 g: 2-year follow-up. Eur Urol. 2006; 2:Suppl 5. 234.

19. Kuntz RM. Laser treatment of benign prostatic hyperplasia. World J Urol. 2007; 25:241–247.

20. Yang HT, Choi NG. Changes and differences of sexual function in patients with benign prostate hyperplasia following transurethral resection of prostate and high energy transurethral microwave thermotherapy. Korean J Urol. 2001; 42:961–966.

21. Perry MJ, Roodhouse AJ, Gidlow AB, Spicer TG, Ellis BW. Thermo-expandable intraprostatic stents in bladder outlet obstruction: an 8-year study. BJU Int. 2002; 90:216–223.

22. Smith RA, von Eschenbach AC, Wender R, Levin B, Byers T, Rothenberger D, Brooks D, Creasman W, Cohen C, Runowicz C, Saslow D, Cokkinides V, Eyre H. ACS Prostate Cancer Advisory Committee. ACS Colorectal Cancer Advisory Committee. ACS Endometrial Cancer Advisory Committee. American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001: testing for early lung cancer detection. CA Cancer J Clin. 2001; 51:38–75.